A federal advisory panel said Monday clinical data wasn’t strong enough to show Teva Pharmaceutical Industries Ltd.'s (TEVA) Parkinson’s disease drug Azilect slows the progression of the disease. Azilect is currently approved in the U.S. to treat the symptoms of Parkinson’s disease. Teva is seeking FDA approval to market the product to slow the clinical progression the neurodegenerative illness. However, the panel of non-FDA medical experts unanimously voted against approval of the product as a drug to alter disease course. The panel vote won’t impact Azilect’s current status as a Parkinson’s disease treatment. According to FDA, Parkinson’s disease drugs currently marked in the U.S. are approved to treat symptoms of the disease.
